MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Psoriatic Arthritis | 14/10/2025 | By Dineshwori
Bio-Thera's BAT2506 Biosimilar to Simponi Gains EMA Review for EU Approval
The reference medicine golimumab has been approved in Europe for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Psoriatic Arthritis | 07/02/2025 | By Abha | 320
UCB Gets FDA Approval for BIMZELX for Treatment of Psoriatic Arthritis
BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Psoriatic Arthritis | 24/09/2024 | By Aishwarya | 710
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy